CASP3 and neoplasm: We also reported previously that the antitumor activity of enavatuzumab has been attributed to three distinct mechanisms of action: (1) direct killing of tumor cells by inducing caspase-3/7 activation, (2) growth inhibition of tumor cell lines through p21-mediated cell cycle arrest, and (3) via antibody dependent cell-mediated cytotoxicity (ADCC) [2, 19].